{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T03:00:36Z","timestamp":1778814036386,"version":"3.51.4"},"reference-count":44,"publisher":"Oxford University Press (OUP)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,1]]},"DOI":"10.1093\/jac\/dkt342","type":"journal-article","created":{"date-parts":[[2013,9,13]],"date-time":"2013-09-13T04:08:24Z","timestamp":1379045304000},"page":"200-210","source":"Crossref","is-referenced-by-count":30,"title":["Clinical and pharmacokinetic considerations for the use of daptomycin in patients with Staphylococcus aureus bacteraemia and severe renal impairment"],"prefix":"10.1093","volume":"69","author":[{"given":"Ricardo L.","family":"Chaves","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abhijit","family":"Chakraborty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Benziger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stacey","family":"Tannenbaum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2013,9,12]]},"reference":[{"key":"key\n\t\t\t\t20170511115847_DKT342C1","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1128\/AAC.45.6.1919-1922.2001","article-title":"In vitro activities of daptomycin against 2,789 clinical isolates from 11 North American medical centers","volume":"45","author":"Barry","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20170511115847_DKT342C2","doi-asserted-by":"crossref","first-page":"4665","DOI":"10.1128\/AAC.48.12.4665-4672.2004","article-title":"Impact of high-inoculum Staphylococcus aureus on the activities of nafcillin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin, in an in vitro pharmacodynamic model","volume":"48","author":"LaPlante","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20170511115847_DKT342C3","first-page":"249","article-title":"Daptomycin use in patients with cancer and neutropenia: data from a retrospective registry","volume":"8","author":"Rolston","year":"2010","journal-title":"Clin Adv Hematol Oncol"},{"key":"key\n\t\t\t\t20170511115847_DKT342C4","first-page":"197","article-title":"Invasive methicillin-resistant Staphylococcus aureus infections among dialysis patients\u2014United States, 2005","volume":"56","author":"Collins","year":"2007","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"key\n\t\t\t\t20170511115847_DKT342C5","doi-asserted-by":"crossref","first-page":"3245","DOI":"10.1128\/AAC.00247-06","article-title":"Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers","volume":"50","author":"Benvenuto","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20170511115847_DKT342C6","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1128\/AAC.48.1.63-68.2004","article-title":"In vivo pharmacodynamic activity of daptomycin","volume":"48","author":"Safdar","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20170511115847_DKT342C7","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1128\/AAC.45.3.845-851.2001","article-title":"Pharmacodynamics of daptomycin in a murine thigh model of Staphylococcus aureus infection","volume":"45","author":"Louie","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20170511115847_DKT342C8","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1093\/jac\/dkg337","article-title":"Pharmacodynamic profile of daptomycin against Enterococcus species and methicillin-resistant Staphylococcus aureus in a murine thigh infection model","volume":"52","author":"Dandekar","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20170511115847_DKT342C9","doi-asserted-by":"crossref","first-page":"2948","DOI":"10.1128\/AAC.44.11.2948-2953.2000","article-title":"Once-daily dosing in dogs optimizes daptomycin safety","volume":"44","author":"Oleson","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl 1","key":"key\n\t\t\t\t20170511115847_DKT342C10","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1086\/647938","article-title":"Daptomycin: from the mountain to the clinic, with essential help from Francis Tally, MD","volume":"50","author":"Eisenstein","year":"2010","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20170511115847_DKT342C11","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1086\/652767","article-title":"Daptomycin exposure and the probability of elevations in the creatine phosphokinase level: data from a randomized trial of patients with bacteremia and endocarditis","volume":"50","author":"Bhavnani","year":"2010","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20170511115847_DKT342C12","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1592\/phco.31.6.527","article-title":"High-dose daptomycin for treatment of complicated Gram-positive infections: a large, multicenter, retrospective study","volume":"31","author":"Kullar","year":"2011","journal-title":"Pharmacotherapy"},{"key":"key\n\t\t\t\t20170511115847_DKT342C13","volume-title":"Cubicin\u00ae (Daptomycin) Summary of Product Characteristics","author":"Novartis Europharm Limited","year":"2012"},{"key":"key\n\t\t\t\t20170511115847_DKT342C14","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.2215\/CJN.08510910","article-title":"Pharmacokinetics and pharmacodynamics of intravenous daptomycin during continuous ambulatory peritoneal dialysis","volume":"6","author":"Cardone","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"key\n\t\t\t\t20170511115847_DKT342C15","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1128\/AAC.36.2.318","article-title":"Single-dose pharmacokinetics and antibacterial activity of daptomycin, a new lipopeptide antibiotic, in healthy volunteers","volume":"36","author":"Woodworth","year":"1992","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20170511115847_DKT342C16","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1128\/AAC.47.4.1318-1323.2003","article-title":"Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects","volume":"47","author":"Dvorchik","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20170511115847_DKT342C17","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.2215\/CJN.01650309","article-title":"Intradialytic administration of daptomycin in end stage renal disease patients on hemodialysis","volume":"4","author":"Salama","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"key\n\t\t\t\t20170511115847_DKT342C18","volume-title":"Cubicin (Daptomycin) Prescribing Infor-mation","author":"Cubist Pharmaceuticals Inc.","year":"2012"},{"key":"key\n\t\t\t\t20170511115847_DKT342C19","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1128\/AAC.01224-10","article-title":"Use of pharmacokinetic and pharmacodynamic principles to determine optimal administration of daptomycin in patients receiving standardized thrice-weekly hemodialysis","volume":"55","author":"Patel","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20170511115847_DKT342C20","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1128\/AAC.47.5.1598-1603.2003","article-title":"Daptomycin dose-effect relationship against resistant Gram-positive organisms","volume":"47","author":"Cha","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20170511115847_DKT342C21","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.ijantimicag.2009.09.021","article-title":"Bactericidal activity of daptomycin versus vancomycin in the presence of human albumin against vancomycin-susceptible but tolerant methicillin-resistant Staphylococcus aureus (MRSA) with daptomycin minimum inhibitory concentrations of 1\u20132 \u03bcg\/mL","volume":"35","author":"Torrico","year":"2010","journal-title":"Int J Antimicrob Agents"},{"key":"key\n\t\t\t\t20170511115847_DKT342C22","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1128\/AAC.48.8.2799-2807.2004","article-title":"Population pharmacokinetics of daptomycin","volume":"48","author":"Dvorchik","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20170511115847_DKT342C23","volume-title":"NONMEM Users Guide","author":"Beal","year":"2009"},{"key":"key\n\t\t\t\t20170511115847_DKT342C24","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1056\/NEJMoa053783","article-title":"Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus","volume":"355","author":"Fowler","year":"2006","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170511115847_DKT342C25"},{"key":"key\n\t\t\t\t20170511115847_DKT342C26","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1086\/589717","article-title":"Staphylococcus aureus bloodstream infections: risk factors, outcomes, and the influence of methicillin resistance in Calgary, Canada, 2000\u20132006","volume":"198","author":"Laupland","year":"2008","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20170511115847_DKT342C27","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s10096-005-1345-3","article-title":"Trends and outcome of nosocomial and community-acquired bloodstream infections due to Staphylococcus aureus in Finland, 1995\u20132001","volume":"24","author":"Lyytikainen","year":"2005","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"key\n\t\t\t\t20170511115847_DKT342C28","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1086\/431979","article-title":"Staphylococcus aureus native valve infective endocarditis: report of 566 episodes from the International Collaboration on Endocarditis Merged Database","volume":"41","author":"Miro","year":"2005","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20170511115847_DKT342C29","doi-asserted-by":"crossref","first-page":"3012","DOI":"10.1001\/jama.293.24.3012","article-title":"Staphylococcus aureus endocarditis: a consequence of medical progress","volume":"293","author":"Fowler","year":"2005","journal-title":"JAMA"},{"key":"key\n\t\t\t\t20170511115847_DKT342C30","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.2215\/CJN.01290308","article-title":"Epidemiology of acute infections among patients with chronic kidney disease","volume":"3","author":"Dalrymple","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"key":"key\n\t\t\t\t20170511115847_DKT342C31","article-title":"Daptomycin efficacy and safety for the treatment of Gram-positive infections in haemodialysis patients: 6 years' clinical experience from EU-CORESM","author":"Nikolaidis"},{"key":"key\n\t\t\t\t20170511115847_DKT342C32","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1093\/jac\/dkm170","article-title":"Evaluation of daptomycin treatment of Staphylococcus aureus bacterial endocarditis: an in vitro and in vivo simulation using historical and current dosing strategies","volume":"60","author":"Rose","year":"2007","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20170511115847_DKT342C33","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1128\/JCM.00660-07","article-title":"Evaluation of endocarditis caused by methicillin-susceptible Staphylococcus aureus developing nonsusceptibility to daptomycin","volume":"46","author":"Sakoulas","year":"2008","journal-title":"J Clin Microbiol"},{"key":"key\n\t\t\t\t20170511115847_DKT342C34","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1128\/AAC.01307-08","article-title":"Relationship between susceptibility to daptomycin in vitro and activity in vivo in the rabbit model of aortic valve endocarditis","volume":"53","author":"Chambers","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20170511115847_DKT342C35","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1056\/NEJMcp0910753","article-title":"Clinical practice. Vertebral osteomyelitis","volume":"362","author":"Zimmerli","year":"2010","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170511115847_DKT342C36","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1517\/14656561003598893","article-title":"Daptomycin: pharmacology and clinical use","volume":"11","author":"Kosmidis","year":"2010","journal-title":"Expert Opin Pharmacother"},{"key":"key\n\t\t\t\t20170511115847_DKT342C37","first-page":"234","article-title":"[Guidelines for the treatment on infections caused by methicillin-resistant Staphylococcus aureus]","volume":"21","author":"Mensa","year":"2008","journal-title":"Rev Esp Quimioter"},{"key":"key\n\t\t\t\t20170511115847_DKT342C38","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.eimc.2008.09.003","article-title":"[Consensus document for the treatment of bacteremia and endocarditis caused by methicillin-resistant Staphylococcus aureus. Sociedad Espanola de Enfermedades Infecciosas y Microbiologia Clinica]","volume":"27","author":"Gudiol","year":"2009","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"key\n\t\t\t\t20170511115847_DKT342C39","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/j.1469-0691.2009.02701.x","article-title":"Management of methicillin-resistant Staphylococcus aureus infections","volume":"15","author":"Garau","year":"2009","journal-title":"Clin Microbiol Infect"},{"key":"key\n\t\t\t\t20170511115847_DKT342C40","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1086\/600039","article-title":"Safety of high-dose intravenous daptomycin treatment: three-year cumulative experience in a clinical program","volume":"49","author":"Figueroa","year":"2009","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20170511115847_DKT342C41","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.ijantimicag.2010.07.011","article-title":"High-dose daptomycin in documented Staphylococcus aureus infections","volume":"36","author":"Bassetti","year":"2010","journal-title":"Int J Antimicrob Agents"},{"key":"key\n\t\t\t\t20170511115847_DKT342C42","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1345\/aph.1M085","article-title":"Safety and clinical outcomes when utilizing high-dose (\u22658 mg\/kg) daptomycin therapy","volume":"43","author":"Moise","year":"2009","journal-title":"Ann Pharmacother"},{"key":"key\n\t\t\t\t20170511115847_DKT342C43","first-page":"63","article-title":"Pharmacokinetics and safety of multiple doses of daptomycin 6 mg\/kg in noninfected adults undergoing hemodialysis or continuous ambulatory peritoneal dialysis","volume":"75","author":"Benziger","year":"2011","journal-title":"Clin Nephrol"},{"key":"key\n\t\t\t\t20170511115847_DKT342C44","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1093\/jac\/dkq528","article-title":"Clinical experience with daptomycin in Europe: the first 2.5 years","volume":"66","author":"Gonzalez-Ruiz","year":"2011","journal-title":"J Antimicrob Chemother"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/69\/1\/200\/16864229\/dkt342.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,8,23]],"date-time":"2017-08-23T14:17:18Z","timestamp":1503497838000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article-lookup\/doi\/10.1093\/jac\/dkt342"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9,12]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2013,9,12]]},"published-print":{"date-parts":[[2014,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkt342","relation":{},"ISSN":["1460-2091","0305-7453"],"issn-type":[{"value":"1460-2091","type":"electronic"},{"value":"0305-7453","type":"print"}],"subject":[],"published":{"date-parts":[[2013,9,12]]}}}